Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Bevacizumab in Recurrent Ovarian Cancer
NCT01091259Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by NYU Langone Health. Started Mar 2010; status: completed.
02
Drugs
irinotecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01091259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091259.